Pyxis Oncology (NASDAQ:PYXS) Cut to Market Perform at William Blair

William Blair downgraded shares of Pyxis Oncology (NASDAQ:PYXS) from an outperform rating to a market perform rating in a research note released on Thursday morning, Marketbeat Ratings reports.

Other equities research analysts have also recently issued research reports about the company. Royal Bank of Canada reiterated an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, August 16th. Stephens initiated coverage on Pyxis Oncology in a research note on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective on the stock. Finally, Stifel Nicolaus began coverage on Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Pyxis Oncology has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Pyxis Oncology Stock Down 9.5 %

Shares of Pyxis Oncology stock opened at $1.90 on Thursday. Pyxis Oncology has a 12-month low of $1.35 and a 12-month high of $6.85. The stock has a market cap of $112.99 million, a P/E ratio of -1.84 and a beta of 1.27. The business’s 50 day moving average is $3.64 and its 200-day moving average is $3.61.

Institutional Investors Weigh In On Pyxis Oncology

Large investors have recently added to or reduced their stakes in the business. Fullcircle Wealth LLC acquired a new position in Pyxis Oncology in the 2nd quarter valued at $40,000. Intech Investment Management LLC acquired a new position in Pyxis Oncology in the 3rd quarter valued at $55,000. SG Americas Securities LLC acquired a new position in Pyxis Oncology in the 3rd quarter valued at $58,000. The Manufacturers Life Insurance Company acquired a new position in Pyxis Oncology in the 2nd quarter valued at $65,000. Finally, MetLife Investment Management LLC grew its holdings in Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after buying an additional 5,484 shares in the last quarter. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.